Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EQ Equillium Inc.

Trading 03-28 11:40:12 EDT

0.4109

-0.0771

-15.80%

High0.4636	Low0.3655	Vol222.85K
Open0.4519	D1 Closing0.4880	Amplitude20.10%
Mkt Cap14.56M	Tradable Cap7.40M	Total Shares35.43M
T/O90.76K	T/O Rate1.24%	Tradable Shares18.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"EQ","market":"US","secType":"STK","nameCN":"Equillium Inc.","latestPrice":0.4109,"timestamp":1743176202223,"preClose":0.488,"halted":0,"volume":222849,"delay":0,"floatShares":18003596,"shares":35430763,"eps":-0.130801,"marketStatus":"Trading","change":-0.0771,"latestTime":"03-28 11:40:12 EDT","open":0.4519,"high":0.4636,"low":0.3655,"amount":90759.38241348001,"amplitude":0.201025,"askPrice":0.411,"askSize":100,"bidPrice":0.41,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-0.130801,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1539316800000,"exchange":"NASDAQ","adjPreClose":0.488,"preHourTrading":{"tag":"盘前","latestPrice":0.428,"preClose":0.488,"latestTime":"09:19 EDT","volume":2652,"amount":1180.1198448,"timestamp":1743167987114},"postHourTrading":{"tag":"盘后","latestPrice":0.4416,"preClose":0.488,"latestTime":"19:49 EDT","volume":46101,"amount":20781.2992,"timestamp":1743119377700},"volumeRatio":2.116728,"impliedVol":1.4019,"impliedVolPercentile":0.344},"requestUrl":"/m/hq/s/EQ","defaultTab":"news","newsList":[{"id":"2522578757","title":"Equillium Cut to Market Perform From Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522578757","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522578757?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:52","pubTimestamp":1743162720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EQ/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 07:52 ET (11:52 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ"],"gpt_icon":0},{"id":"2522573178","title":"Equillium Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573178","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573178?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:35","pubTimestamp":1743161752,"startTime":"0","endTime":"0","summary":"NasdaqCM:EQ Earnings and Revenue History March 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 12%. Earnings per share  also surpassed analyst estimates by 39%.Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 39% from a week ago.You should always think about risks. Case in point, we've spotted   4 warning signs for Equillium  you should be aware of, and 2 of them are a bit concerning.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-full-2024-earnings-beats-113552162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EQ"],"gpt_icon":0},{"id":"2522527498","title":"Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527498?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:24","pubTimestamp":1743161050,"startTime":"0","endTime":"0","summary":"Equillium (EQ) has an average rating of overweight and mean price target of $3, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQ"],"gpt_icon":0},{"id":"2522527340","title":"Equillium Inc : Leerink Partners Cuts to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527340?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:15","pubTimestamp":1743160539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2522529837","title":"Equillium downgraded to Market Perform from Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2522529837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522529837?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 18:16","pubTimestamp":1743157011,"startTime":"0","endTime":"0","summary":"Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1, down from $3. The company repor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/equillium-downgraded-to-market-perform-from-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/equillium-downgraded-to-market-perform-from-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQ","BK4139","BK4568"],"gpt_icon":0},{"id":"2522652584","title":"Equillium Inc : Leerink Partners Cuts Target Price to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522652584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522652584?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 18:03","pubTimestamp":1743156209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB071:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522589511","title":"Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522589511","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522589511?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 00:12","pubTimestamp":1743091973,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44519152/gold-gains-1-td-synnex-shares-plunge-after-downbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","QID","GTEC","BK4207","BK4139","TSYW.SI","PSQ","TQQQ","EQ","BK4161","BK4568",".IXIC","MNQmain","BK4539","BK4561","TD","BK4140","SLNO","USJW.SI","BK4214","DRMA","SQQQ","NXU","BK4023","NQmain","USAW.SI","BK4566","AUUD","BK4007","QLD","BK4149","SNX","NVIW.SI"],"gpt_icon":1},{"id":"2522339379","title":"Equillium reports EQUATOR study did not improve complete, overall response rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522339379","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522339379?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:16","pubTimestamp":1743074208,"startTime":"0","endTime":"0","summary":"Equillium (EQ) announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-ver...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/equillium-reports-equator-study-did-not-improve-complete-overall-response-rates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/equillium-reports-equator-study-did-not-improve-complete-overall-response-rates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2522768413","title":"BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522768413","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522768413?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:13","pubTimestamp":1743073991,"startTime":"0","endTime":"0","summary":"BRIEF-Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host DiseaseMarch 27 (Reuters) - Equillium Inc EQ.O:EQUILLIUM ANNOUNCES RESULTS OF THE PHASE 3 EQUATOR STUDY OF ITOLIZUMAB ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522375002","title":"BRIEF-Equillium Reports Fourth Quarter and FY 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375002?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:11","pubTimestamp":1743073905,"startTime":"0","endTime":"0","summary":"BRIEF-Equillium Reports Fourth Quarter and FY 2024 Results March 27 (Reuters) - Equillium Inc EQ.O:EQUILLIUM Q4 REVENUE USD 4.392 MILLIONEQUILLIUM Q4 OPERATING INCOME USD -4.697 MILLIONEQUILLIUM Q4 BA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXD01E37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ","BK4568","BK4139"],"gpt_icon":0},{"id":"2522837537","title":"Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837537?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6TSVHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2522759993","title":"Equillium Inc - Breakthrough Therapy Designation Request Submitted to FDA, Feedback Expected During May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759993?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2522755943","title":"Equillium Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients With Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522755943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522755943?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2522375980","title":"Equillium Inc - Itolizumab Did Not Improve Response Rates at Day 29","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375980?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2522375931","title":"Equillium Inc - Itolizumab Achieved Statistical Significance in Longer-Term Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375931?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAJWXM1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522637559","title":"Equillium Q4 Revenue USD 4.392 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522637559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522637559?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXD01E37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2522537175","title":"Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537175","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537175?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Treatment with itolizumab did not improve complete or overall response rates at Day 29. Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival. Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. Management will host a conference call and webcast today at 8:30 am ET. \"The longer-term outcomes are important,\" said Dr. John Koreth, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School. \"There are no approvals in first-line therapy for aGVHD, and no drug candidates have been able to demonstrate efficacy beyond four weeks. To demonstrate statistical significance in pre-specified endpoints of duration of complete response and failure-free survival, compared to standard of care therapy, is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-announces-results-phase-3-110000303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4139","LU0054578231.USD","BK4568","HST","BK4588","ORR","LU0053671581.USD","BK4585","BK4161","ITT","BK4181","BK4218","EQ"],"gpt_icon":0},{"id":"2522429371","title":"Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522429371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522429371?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. LA JOLLA, Calif., March 27, 2025----Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease  demonstrating a favorable safety and tolerability profile, and clinically meaningful longer-term outcomes. There was no meaningful difference in complete response  and overall response rate  at Day 29 between itolizumab patients and placebo patients, but statistical significance and/or clinically meaningful benefit in longer term outcomes were achieved by itolizumab in the following measurements","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-reports-fourth-quarter-full-110000383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","EQ","BK4161","ORR","BK4139","BK4568"],"gpt_icon":0},{"id":"2521461225","title":"Ethisphere Recognizes Applied Materials with Compliance Leader Verification(TM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521461225","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521461225?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 00:00","pubTimestamp":1742486400,"startTime":"0","endTime":"0","summary":"Award recognizes organizations with an outstanding commitment to achieving a best-in-class ethics and compliance program. SCOTTSDALE, AZ / ACCESS Newswire / March 20, 2025 / Ethisphere, a global leader in defining and advancing the standards of ethical business practices, announced today that Applied Materials, Inc. has earned the coveted Compliance Leader Verification for 2025 and 2026.Applied Materials is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. The company's technology enables high-performance, energy-efficient semiconductors to power the world's most critical electronic systems, from AI data centers to electric vehicles.Ethisphere is the global leader in defining and advancing the standards of ethical business practices that fuel corporate character, marketplace trust, and business success. Ethisphere has deep expertise in measuring and defining core ethics standards using data-driven insights that hel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ethisphere-recognizes-applied-materials-compliance-160000288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TM","BK4567","SG9999001424.SGD","ARKG","LU2271345857.HKD","IE00BD6J9T35.USD","LU1046421795.USD","LU2023251221.USD","BK4555","BK4604","BK4516","BK4147","LU1674673428.USD","LU0868494708.USD","LU1989773731.SGD","SG9999002232.USD","LU0957791311.USD","IE00BQXX3F31.USD","LU0096362180.USD","LU1974910355.USD","03160","IE00BSNM7G36.USD","LU0792757196.USD","BK4139","LU0889566641.SGD","AMAT","LU0868494617.USD","IE0009356076.USD","IE00BQXX3C00.GBP","SG9999002224.SGD","BK4533","LU2111349929.HKD","BK4588","LU2458330243.SGD","LU0354030438.USD","LU0444971666.USD","LU1803068979.SGD","LU0109392836.USD","BK4544","LU1153585028.USD","LU0476273544.USD","LU1823568750.SGD","LU2023250504.SGD","LU1674673691.USD","IE00BQXX3D17.EUR","EQ","LU1778281490.HKD","LU0957808578.USD","IE00B5949003.HKD","LU1267930813.SGD"],"gpt_icon":0},{"id":"2520652322","title":"EQ Resources Limited Requests Trading Halt Pending Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652322?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 11:08","pubTimestamp":1742267301,"startTime":"0","endTime":"0","summary":"An update from EQ Resources Limited ( ($AU:EQR) ) is now available. EQ Resources Limited has requested a trading halt on its securities on the Aust...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-requests-trading-halt-pending-announcement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eq-resources-limited-requests-trading-halt-pending-announcement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQ","BK4568","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.equilliumbio.com","stockEarnings":[{"period":"1week","weight":-0.39},{"period":"1month","weight":-0.3789},{"period":"3month","weight":-0.2968},{"period":"6month","weight":-0.4136},{"period":"1year","weight":-0.7631},{"period":"ytd","weight":-0.3478}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.074209},{"month":2,"riseRate":0.571429,"avgChangeRate":0.328463},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.172587},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.172176},{"month":5,"riseRate":0.833333,"avgChangeRate":0.054615},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.145316},{"month":7,"riseRate":0.5,"avgChangeRate":0.343945},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073981},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.069941},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.079943},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.050609},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.119129}],"exchange":"NASDAQ","name":"Equillium Inc.","nameEN":"Equillium Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Equillium Inc.(EQ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Equillium Inc.,EQ,Equillium Inc.股票,Equillium Inc.股票老虎,Equillium Inc.股票老虎国际,Equillium Inc.行情,Equillium Inc.股票行情,Equillium Inc.股价,Equillium Inc.股市,Equillium Inc.股票价格,Equillium Inc.股票交易,Equillium Inc.股票购买,Equillium Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Equillium Inc.(EQ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Equillium Inc.(EQ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}